At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
CR crane
Pre-Mkt 03-20 08:40:25 EDT
174.28
-0.80
-0.46%
盘前174.62
+0.34+0.20%
08:09 EDT
High175.57Low170.27Vol302.97K
Open172.40D1 Closing175.08Amplitude3.03%
Mkt Cap10.04BTradable Cap8.50BTotal Shares57.60M
T/O52.46MT/O Rate0.62%Tradable Shares48.76M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

Press Release: Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
Dow Jones  ·  04:01
Press Release: Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
GlobeNewswire  ·  03-19 20:36
Moleculin Reports Full Year 2025 Financial Results and Confirms Highly Anticipated 45-Patient Interim Data Unblinding in Pivotal MIRACLE Trial On Track for Mid-2026
Crane Company publishes 2025 annual report, net sales rise 8%
Reuters  ·  03-13
Crane Company publishes 2025 annual report, net sales rise 8%
Crane Company announces annual stockholders meeting
Reuters  ·  03-13
Crane Company announces annual stockholders meeting
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
GlobeNewswire  ·  03-10
Protara Therapeutics Announces Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
Press Release: enGene Reports First Quarter 2026 Financial Results and Provides Business Update
Dow Jones  ·  03-09
Press Release: enGene Reports First Quarter 2026 Financial Results and Provides Business Update
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
GlobeNewswire  ·  03-09
Relmada Therapeutics Reports 12-Month Phase 2 Interim Data for NDV-01 in Non-Muscle Invasive Bladder Cancer
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
GlobeNewswire  ·  03-05
Medicus Pharma Reports Positive Phase 2 SKNJCT-003 Topline Data Observing 73% Clinical Clearance and 40% Histological Clearance (CR) at Day 57 in 200μg Cohort
Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025
Dow Jones  ·  02-28
Press Release: ORYZON Reports Financial Results and Corporate Update for Quarter Ended December 31st, 2025
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
GlobeNewswire  ·  02-27
ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
GlobeNewswire  ·  02-27
ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update
Federal Signal Appoints Rich Maue and Eric Vaillancourt to Board
Reuters  ·  02-27
Federal Signal Appoints Rich Maue and Eric Vaillancourt to Board
Crane posts FY 2025 operating profit USD 424.2 million +19.2%
Reuters  ·  02-27
Crane posts FY 2025 operating profit USD 424.2 million +19.2%
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
GlobeNewswire  ·  02-25
Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
GlobeNewswire  ·  02-18
Moleculin MIRACLE Trial Delivers 40% Preliminary Blinded CRc Rate (n=30)
Crane CEO buys $183.7K in common stock
TIPRANKS  ·  02-03
Crane CEO buys $183.7K in common stock
Crane Company Chairman, President and CEO Max H. Mitchell Acquires Common Shares
Reuters  ·  02-03
Crane Company Chairman, President and CEO Max H. Mitchell Acquires Common Shares
Crane Company Names Alex Alcala CEO as Max Mitchell Becomes Executive Chairman
Reuters  ·  01-30
Crane Company Names Alex Alcala CEO as Max Mitchell Becomes Executive Chairman
Crane Is Maintained at Buy by DA Davidson
Dow Jones  ·  01-30
Crane Is Maintained at Buy by DA Davidson
Crane Taps Operating Chief as New CEO, Raises Dividend
Dow Jones  ·  01-27
Crane Taps Operating Chief as New CEO, Raises Dividend

Introduction

Company Name.
crane
Affiliated Markets:
NYSE
Listing Date:
--
Main Business:
Crane NXT, Co. focuses on payment and merchandising technologies. It indents to offer electronic equipment and associated software leveraging extensive, and proprietary core capabilities, including payment verification and authentication, as well as automation solutions, field service solutions, remote diagnostics, and productivity enhancing software solutions. The company is based in Stamford, Connecticut.
Issue price:
--